Cargando…

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

Alzheimer’s disease (AD) is a neurodegenerative disorder affecting millions of people around the world. The two main pathological mechanisms underlying the disease are beta-amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFTs) of Tau proteins in the brain. Their reduction has been as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silvestro, Serena, Valeri, Andrea, Mazzon, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8880389/ https://www.ncbi.nlm.nih.gov/pubmed/35216126 http://dx.doi.org/10.3390/ijms23042011

Ejemplares similares

Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease
por: Schepici, Giovanni, et al.
Publicado: (2020)

Aducanumab-Related Amyloid-Related Imaging Abnormalities: Paean or Lament?
por: Høilund-Carlsen, Poul F., et al.
Publicado: (2022)

Reconsideration of Amyloid Hypothesis and Tau Hypothesis in Alzheimer's Disease
por: Kametani, Fuyuki, et al.
Publicado: (2018)

Is Aducanumab for LMICs? Promises and Challenges
por: Gunawardena, Illangage P. C., et al.
Publicado: (2021)

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
por: Arndt, Joseph W., et al.
Publicado: (2018)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

MiRNAs as Promising Translational Strategies for Neuronal Repair and Regeneration in Spinal Cord Injury
por: Silvestro, Serena, et al.
Publicado: (2022)

Nrf2 Activation: Involvement in Central Nervous System Traumatic Injuries. A Promising Therapeutic Target of Natural Compounds
por: Silvestro, Serena, et al.
Publicado: (2022)

Regenerative Effects of Exosomes-Derived MSCs: An Overview on Spinal Cord Injury Experimental Studies
por: Schepici, Giovanni, et al.
Publicado: (2023)

Aducanumab—Hope or Disappointment for Alzheimer’s Disease
por: Wojtunik-Kulesza, Karolina, et al.
Publicado: (2023)

Quantitative systems pharmacology model for Alzheimer’s disease to predict the effect of aducanumab on brain amyloid
por: Lin, Lin, et al.
Publicado: (2022)

Aducanumab for Alzheimer’s disease?
por: Walsh, Sebastian, et al.
Publicado: (2021)

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab
por: Shi, Mingchao, et al.
Publicado: (2022)

Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2023)

Role of miRNAs in Alzheimer’s Disease and Possible Fields of Application
por: Silvestro, Serena, et al.
Publicado: (2019)

MicroRNAs and MAPKs: Evidence of These Molecular Interactions in Alzheimer’s Disease
por: Raffaele, Ivana, et al.
Publicado: (2023)

Modulating Stress Proteins in Response to Therapeutic Interventions for Parkinson’s Disease
por: Silvestro, Serena, et al.
Publicado: (2023)

Aducanumab: What about the Patient?
por: Petersen, Ronald C.
Publicado: (2021)

Aducanumab: Appropriate use recommendations
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations
por: Cummings, J., et al.
Publicado: (2021)

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
por: Vaz, Miguel, et al.
Publicado: (2022)

Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
por: Valeri, Andrea, et al.
Publicado: (2021)

State of the Art and Future of Stem Cell Therapy in Ischemic Stroke: Why Don’t We Focus on Their Administration?
por: Valeri, Andrea, et al.
Publicado: (2023)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
por: Mattsson‐Carlgren, Niklas, et al.
Publicado: (2021)

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
por: Silvestro, Serena, et al.
Publicado: (2020)

The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
por: Schepici, Giovanni, et al.
Publicado: (2019)

Stem Cells Therapy for Spinal Cord Injury: An Overview of Clinical Trials
por: Silvestro, Serena, et al.
Publicado: (2020)

Traumatic Brain Injury and Stem Cells: An Overview of Clinical Trials, the Current Treatments and Future Therapeutic Approaches
por: Schepici, Giovanni, et al.
Publicado: (2020)

A State of the Art of Antioxidant Properties of Curcuminoids in Neurodegenerative Diseases
por: Silvestro, Serena, et al.
Publicado: (2021)

Aducanumab: Appropriate Use Recommendations Update
por: Cummings, J., et al.
Publicado: (2022)

Practical Considerations in the Administration of Aducanumab for the Neurologist
por: Coerver, Katherine, et al.
Publicado: (2022)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab
por: VandeVrede, Lawren, et al.
Publicado: (2020)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic: Their Role in Alzheimer’s Pathogenesis
por: Penke, Botond, et al.
Publicado: (2020)

Mitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
por: Esteras, Noemi, et al.
Publicado: (2020)

Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review
por: Beshir, Semira Abdi, et al.
Publicado: (2022)

Intracellular amyloid hypothesis for ultra‐early phase pathology of Alzheimer's disease
por: Okazawa, Hitoshi
Publicado: (2021)

Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration
por: Höglund, K, et al.
Publicado: (2017)

Cannabidiol Promotes Neuronal Differentiation Using Akt and Erk Pathways Triggered by Cb1 Signaling
por: Blando, Santino, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3s84je45s9q61vfgqqn64aub5k